NASDAQ:SPRO Spero Therapeutics (SPRO) Stock Price, News & Analysis $0.90 -0.05 (-4.77%) Closing price 04:00 PM EasternExtended Trading$0.94 +0.04 (+4.52%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Spero Therapeutics Stock (NASDAQ:SPRO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Spero Therapeutics alerts:Sign Up Key Stats Today's Range$0.88▼$0.9450-Day Range$0.90▼$1.3652-Week Range$0.88▼$3.08Volume332,475 shsAverage Volume355,506 shsMarket Capitalization$52.51 millionP/E Ratio11.83Dividend YieldN/APrice Target$6.00Consensus RatingHold Company Overview Spero Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for serious and difficult-to-treat bacterial infections. Its work has centered on antibiotic candidates intended to address infections for which existing treatment options may be limited. The company’s pipeline has included tebipenem HBr, an oral antibiotic candidate studied for complicated urinary tract infections, and programs targeting drug-resistant Gram-negative bacteria and nontuberculous mycobacterial infections. Spero has also pursued development and commercialization partnerships, including a collaboration with GSK on tebipenem. Based in Cambridge, Massachusetts, Spero has conducted its development activities primarily through research, clinical testing and partnerships. Its programs and development plans may change as clinical results and regulatory reviews evolve.AI Generated. May Contain Errors. Read More Spero Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreSPRO MarketRank™: 4.367365905465 of 5 starsSpero Therapeutics scored higher than 87% of companies evaluated by MarketBeat, and ranked 71st out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingSpero Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 2 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialSpero Therapeutics has a consensus price target of $6.00, representing about 565.7% upside from its current price of $0.90.Amount of Analyst CoverageSpero Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Spero Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Spero Therapeutics are expected to grow in the coming year, from ($0.97) to ($0.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spero Therapeutics is 11.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Spero Therapeutics is 11.83, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.17.Price to Book Value per Share RatioSpero Therapeutics has a P/B Ratio of 90.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.39% of the float of Spero Therapeutics has been sold short.Short Interest Ratio / Days to CoverSpero Therapeutics has a short interest ratio ("days to cover") of 2.23, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spero Therapeutics has recently decreased by 6.37%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSpero Therapeutics does not currently pay a dividend.Dividend GrowthSpero Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.01 News SentimentSpero Therapeutics has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Spero Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Spero Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Spero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,485.00 in company stock.Percentage Held by Insiders2.90% of the stock of Spero Therapeutics is held by insiders.Percentage Held by Institutions25.60% of the stock of Spero Therapeutics is held by institutions.Read more about Spero Therapeutics' insider trading history. Receive SPRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPRO Stock News HeadlinesSpero Therapeutics (NASDAQ:SPRO) Cut to "Strong Sell" at Wall Street ZenNovember 17 at 3:23 AM | americanbankingnews.comSpero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 13, 2026 | marketscreener.comMUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washington is set to take place by November 30th. He believes it could create one of the most chaotic environments in America's history. He predicts those who understand what's happening could do very well over the next 12-18 months, while others may face steep losses. Rickards outlines the five steps he recommends.November 17 at 1:00 AM | Paradigm Press (Ad)Spero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business UpdateNovember 12, 2026 | globenewswire.comSpero Therapeutics, Inc. Announces Board and Committee ChangesNovember 11, 2026 | marketscreener.comMSpero Therapeutics Appoints William Ho, M.D., Ph.D., to its Board of DirectorsNovember 10, 2026 | finance.yahoo.comSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 4, 2026 | globenewswire.comSpero Therapeutics to Present at Investor Conferences in NovemberNovember 2, 2026 | globenewswire.comSee More Headlines SPRO Stock Analysis - Frequently Asked Questions How have SPRO shares performed this year? Spero Therapeutics' stock was trading at $2.33 at the beginning of the year. Since then, SPRO shares have decreased by 61.3% and is now trading at $0.9013. How were Spero Therapeutics' earnings last quarter? Spero Therapeutics, Inc. (NASDAQ:SPRO) released its quarterly earnings results on Thursday, November, 12th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $0.29. Spero Therapeutics had a net margin of 24.90% and a trailing twelve-month return on equity of 13.98%. When did Spero Therapeutics IPO? Spero Therapeutics (SPRO) raised $82 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,500,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager. Who are Spero Therapeutics' major shareholders? Top institutional shareholders of Spero Therapeutics include State Street Corp (0.43%), Marshall Wace LLP (0.34%) and Empowered Funds LLC (0.11%). Insiders that own company stock include Sath Shukla, Esther Rajavelu, Ankit Mahadevia and Timothy Keutzer. View institutional ownership trends. How do I buy shares of Spero Therapeutics? Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Spero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spero Therapeutics investors own include Editas Medicine (EDIT), Aktis Oncology (AKTS), Heron Therapeutics (HRTX), Nokia (NOK), Arcturus Therapeutics (ARCT), Corning (GLW) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings11/12/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SPRO's financial health is in the Red zone, according to TradeSmith. SPRO has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SPRO CIK1701108 Websperotherapeutics.com Phone(857) 242-1600FaxN/AEmployees25Year Founded2013Price Target and Rating Average Price Target for Spero Therapeutics$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside+565.7%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.52) Trailing P/E Ratio11.83 Forward P/E RatioN/A P/E GrowthN/ANet Income$8.57 million Net Margins24.90% Pretax Margin-70.39% Return on Equity13.98% Return on Assets7.55% Debt Debt-to-Equity RatioN/A Current Ratio1.92 Quick Ratio1.92 Sales & Book Value Annual Sales$66.80 million Price / Sales0.79 Cash Flow$0.14 per share Price / Cash Flow6.22 Book Value$0.01 per share Price / Book90.13Miscellaneous Outstanding Shares58,260,000Free Float56,546,000Market Cap$52.51 million OptionableOptionable Beta1.59 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:SPRO) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.